

Application No. 09/693,558

Page 17

*Sub E*

D is selected from the group consisting of C<sub>2</sub> - C<sub>6</sub> alkylene and C<sub>2</sub> - C<sub>6</sub> alkenylene, where the double bond may also join D and E;

E is selected from the group consisting of pyrrolidine, piperidine, hexahydroazepine, and morpholine; and

*15 cont*

G is selected from the group consisting of benzyl, phenethyl, fluorenylmethyl, anthrylmethyl, diphenylmethyl, fluorenyl, dihydrodibenzocycloheptenyl, furylmethyl, thienylmethyl, thiazolylmethyl, pyridylmethyl, benzothienylmethyl, quinolylmethyl, phenylthienylmethyl, phenylpyridylmethyl, dihydrodibenzoxepinyl, dihydrodibenzothiepinyl, acetyl, pivaloyl, phenylacetyl, diphenylacetyl, diphenylpropionyl, naphthylacetyl, benzoyl, naphthoyl, anthrylcarbonyl, oxofluorenylcarbonyl, oxodihydroanthrylcarbonyl, dioxodihydroanthrylcarbonyl, furoyl, pyridylcarbonyl, chromonylcarbonyl, quinolylcarbonyl, naphthylaminocarbonyl, dibenzylaminocarbonyl, benzylphenylaminocarbonyl, diphenylaminocarbonyl, indolin-1-ylcarbonyl, dihydrodibenzazepinyl-N-carbonyl, tetrahydroquinolinyl-N-carbonyl, tetrahydrobenzazepinyl-N-carbonyl, methanesulfonyl, benzenesulfonyl, p-toluenesulfonyl, naphthalenesulfonyl, quinolinesulfonyl, and diphenylphosphinoyl, where the or each aromatic ring system may be independently substituted with one to three substituents selected independently from the group consisting of halogen, cyano, C<sub>1</sub> - C<sub>6</sub> alkyl, trifluoromethyl, C<sub>3</sub> - C<sub>8</sub> cycloalkyl, phenyl, benzyl, hydroxy, C<sub>1</sub> - C<sub>6</sub> alkoxy (optionally partially or completely fluorinated), benzyloxy, phenoxy, mercapto, C<sub>1</sub> - C<sub>6</sub> alkylthio, carboxy, C<sub>1</sub> - C<sub>6</sub> alkoxycarbonyl, benzyloxycarbonyl, nitro, amino, C<sub>1</sub> - C<sub>6</sub> alkylamino, and di(C<sub>1</sub> - C<sub>6</sub> alkyl)amino, or two adjacent substituents together form methylenedioxy.

#### REMARKS

Entry of this amendment is respectfully requested. No new matter is added by the amendment, because the amended application is fully supported by the application as filed.

Claims 32 - 52 are in this application; no claims having been cancelled, claims 37, 39, 40, 42-46, 48, and 19 having been amended, and claims 50 - 52 having been added by this amendment.

The amendment:

- (1) corrects the dependency of claims 37 and 48 so that the case where the compound having vitamin PP activity is tryptophan is dependent only on a claim where the compound is not defined as being of formulae II through Vb (claims 32 and 51 respectively);
- (2) adds a new claim 50, dependent from claim 38, further limiting the scope of the cancerostatic/immunosuppressive agents of formula I to those of formula Ia (see pages 26 - 28 of the specification), and amends claims 39 and 40 to be dependent from that new claim 50;
- (3) adds a new claim 51 in which the compound having vitamin PP activity is defined only in that way and not as being of formulae II through Vb, as in claim 41;
- (4) adds a new claim 52 in which the compound of formula I is further limited to a compound of formula Ia; and

**BEST AVAILABLE COPY**

Application No. 09/693,558

Page 18

(5) amends the dependency of claims originally dependent on claim 41 (except claim 48) to make them dependent on claim 52, and modifies "formula I" to "formula Ia" where needed.

Claims reading on the elected species [where the compound having vitamin PP activity is nicotinamide and the cancerostatic/immunosuppressive compound is N-[4-(1-benzoylpiperidin-4-yl)-butyl]-3-(pyridin-3-yl)acrylamide] are claims 32-36, 38-47, and 49-52.

The Examiner is thanked for the courtesy of a telephonic interview in early September at which this application was discussed.

In that interview, Applicants' attorney advised the Examiner that he believed that the Office Action was defective in that the Examiner had failed to examine the elected species by not examining the cancerostatic/immunosuppressive compounds of formula I where E and G is a heterocycle, since the elected compound is one in which E is piperidin-4-yl, which is heterocyclic.

Applicants respectfully request that the Office Action be withdrawn and that a new Office Action be issued in which the elected species is examined.


To simplify further examination, Applicants have responded to the formal rejections of claims 37 and 48 made in the Office Action and have introduced further claims free of the term "functional group" that was the basis for the rejection of claims 38-40.

#### Conclusion

Attached hereto is a marked up copy of the changes made to the application by the current amendment. The attached pages are captioned "Amendments to show changes made".

Entry of the amendment, and issuance of a new Office Action are respectfully requested.

Respectfully submitted,



Derek P. Freyberg  
Attorney for Applicants  
Reg. No. 29,250

Customer No.: 25213  
Heller Ehrman White & McAuliffe LLP  
275 Middlefield Road  
Menlo Park, CA 94025-3506  
(650) 324-7014  
October 10, 2002

**Amendments to show changes made**  
**(Additions underlined, deletions in strikethrough)**

**Claims 37, 39, 40, 42-46, 48, and 49:**

37.(Amended) The method of claim 32 ~~35~~ where the compound having vitamin PP activity or a prodrug thereof is tryptophan.

39.(Amended) The method of claim 50 ~~38~~ where the cancerostatic or immunosuppressive agent is selected from the group consisting of

N-[2-(1-benzylpiperidin-4-yl)ethyl]-3-(pyridin-3-yl)propionamide;  
N-{2-[1-(2-phenylethyl)piperidin-4-yl]ethyl}-3-(pyridin-3-yl)-propionamide;  
N-{2-[1-(4-phenylbutyl)piperidin-4-yl]ethyl}-3-(pyridin-3-yl)-propionamide;  
N-{2-[1-(4-hydroxy-4-phenylbutyl)piperidin-4-yl]ethyl}-3-(pyridin-3-yl)propionamide;  
N-[2-(1-diphenylmethylpiperidin-4-yl)ethyl]-3-(pyridin-3-yl)-propionamide,  
N-[3-(1-diphenylmethylpiperidin-4-yl)propyl]-3-(pyridin-3-yl)propionamide;  
N-[4-(1-diphenylmethylpiperidin-4-yl)butyl]-3-(pyridin-3-yl)propionamide;  
N-[4-(1-benzylpiperidin-4-yl)butyl]-3-(pyridin-3-yl)acrylamide;  
N-{4-[1-(2-phenylethyl)piperidin-4-yl]butyl}-3-(pyridin-3-yl)-acrylamide;  
N-{4-[1-(4-biphenylmethyl)piperidin-4-yl]butyl}-3-(pyridin-3-yl)acrylamide;  
N-{4-[1-(1-naphthylmethyl)piperidin-4-yl]butyl}-3-(pyridin-3-yl)acrylamide;  
N-{4-[1-(9-anthrylmethyl)piperidin-4-yl]butyl}-3-(pyridin-3-yl)acrylamide;  
N-{4-[1-(cyclohexylphenylmethyl)piperidin-4-yl]butyl}-3-(pyridin-3-yl)acrylamide;  
N-{4-[1-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)piperidin-4-yl]butyl}-3-(pyridin-3-yl)-acrylamide;  
N-[2-(1-diphenylmethylpiperidin-4-yl)ethyl]-3-(pyridin-3-yl)acrylamide;  
N-[3-(1-diphenylmethylpiperidin-4-yl)propyl]-3-(pyridin-3-yl)acrylamide;  
N-[5-(1-diphenylmethylpiperidin-4-yl)pentyl]-3-(pyridin-3-yl)acrylamide;  
N-[6-(1-diphenylmethylpiperidin-4-yl)hexyl]-3-(pyridin-3-yl)acrylamide;  
N-[4-(1-diphenylmethylpiperidin-4-yl)butyl]-5-(pyridin-3-yl)-2,4-pentadienic acid amide;  
N-(4-{1-[bis(4-fluorophenyl)methyl]piperidin-4-yl}butyl)-3-(pyridin-3-yl)acrylamide;  
N-(4-{1-[bis(2-chlorophenyl)methyl]piperidin-4-yl}butyl)-3-(pyridin-3-yl)acrylamide;  
N-[4-(1-diphenylmethylpiperidin-4-yl)butyl]-3-(2-fluoro-pyridin-3-yl)acrylamide;

Application No. 09/693,558

Page 20

N-[4-(1-diphenylmethylpiperidin-4-yl)butyl]-3-(6-fluoro-pyridin-3-yl)acrylamide;  
N-[4-(1-diphenylmethylpiperidin-4-yl)butyl]-3-(pyridin-3-yl)acrylamide;  
N-[4-(1-diphenylmethylpiperidin-4-yl)butyl]-3-(pyridin-3-yl)acrylamide dihydrochloride;  
N-[4-(1-diphenylmethylpiperidin-4-yl)butyl]-3-(pyridin-3-yl)acrylamide methanesulfonate;  
N-[4-(1-acetylpiperidin-4-yl)butyl]-3-(pyridin-3-yl)propionamide;  
N-[4-(1-benzoylpiperidin-4-yl)butyl]-3-(pyridin-3-yl)propionamide;  
N-[4-(1-diphenylacetylpiperidin-4-yl)butyl]-3-(pyridin-3-yl)propionamide;  
N-[4-[1-(9-oxo-9H-fluoren-4-carbonyl)piperidin-4-yl]butyl]-3-(pyridin-3-yl)propionamide;  
N-[4-(1-methylsulfonylpiperidin-4-yl)butyl]-3-(pyridin-3-yl)propionamide;  
N-[4-[1-(2-naphthylsulfonyl)piperidin-4-yl]butyl]-3-(pyridin-3-yl)propionamide;  
N-[4-(1-benzylpiperidin-4-yl)butyl]-3-(pyridin-3-yl)propionamide;  
N-[4-{1-[bis(2-chlorophenyl)methyl]piperidin-4-yl}butyl]-3-(pyridin-3-yl)propionamide;  
N-[4-[1-(phenylpyridin-3-ylmethyl)piperidin-4-yl]butyl]-3-(pyridin-3-yl)propionamide;  
N-[4-[1-(9H-fluoren-9-yl)piperidin-4-yl]butyl]-3-(pyridin-3-yl)propionamide;  
N-[4-[1-(6,11-dihydrodibenzo[b,e]oxepin-11-yl)piperidin-4-yl]butyl]-3-(pyridin-3-yl)propionamide;  
N-[4-[1-(1-naphthylaminocarbonyl)piperidin-4-yl]butyl]-3-(pyridin-3-yl)propionamide;  
N-[4-(1-diphenylaminocarbonylpiperidin-4-yl)butyl]-3-(pyridin-3-yl)propionamide;  
N-[4-[1-(10,11-dihydrodibenzo[b,f]azepin-5-yl-carbonyl)piperidin-4-yl]butyl]-3-(pyridin-3-yl)-  
propionamide;  
N-[4-(1-diphenylphosphinoylpiperidin-4-yl)butyl]-3-(pyridin-3-yl)propionamide;  
N-[4-(1-diphenylmethylpiperidin-4-yl)butyl]-3-(2-fluoropyridin-3-yl)propionamide;  
N-[4-(1-diphenylmethylpiperidin-4-yl)butyl]-3-(5-fluoropyridin-3-yl)propionamide;  
N-[4-(1-diphenylmethylpiperidin-4-yl)butyl]-2-fluoro-3-(pyridin-3-yl)propionamide;  
N-[4-(1-diphenylmethylpiperidin-4-yl)butyl]-2,2-difluoro-3-(pyridin-3-yl)propionamide;  
N-[5-(1-diphenylmethylpiperidin-4-yl)pentyl]-3-(pyridin-3-yl)propionamide;  
N-[6-(1-diphenylmethylpiperidin-4-yl)hexyl]-3-(pyridin-3-yl)propionamide;  
N-[2-(1-diphenylmethylpiperidin-4-yl)ethyl]-5-(pyridin-3-yl)pentanoic acid amide;  
N-[4-(1-diphenylmethylpiperidin-4-yl)butyl]-5-(pyridin-3-yl)pentanoic acid amide;  
N-[4-(1-diphenylmethylpiperidin-4-yl)butyl]-N-hydroxy-3-(pyridin-3-yl)propionamide;  
N-[4-(1-diphenylmethylpiperidin-4-yl)butyl]-2-hydroxy-3-(pyridin-3-yl)propionamide;  
N-[4-(1-diphenylmethylpiperidin-4-yl)butyl]-3-hydroxy-3-(pyridin-3-yl)propionamide;  
N-[4-(1-diphenylmethylpiperidin-4-yl)butyl]-3-(pyridin-3-yl)propionamide;

Application No. 09/693,558

Page 21

N-[4-(1-methylsulfonylpiperidin-4-yl)butyl]-3-(pyridin-3-yl)acrylamide;  
N-{4-[1-(2-naphthylsulfonyl)piperidin-4-yl]butyl}-3-(pyridin-3-yl)acrylamide;  
N-{4-[1-(2-naphthylsulfonyl)piperidin-4-yl]butyl}-5-(pyridin-3-yl)-2,4-pentadienic acid amide;  
N-{4-[1-(1-naphthylaminocarbonyl)piperidin-4-yl]butyl}-3-(pyridin-3-yl)acrylamide;  
N-[4-(1-diphenylaminocarbonylpiperidin-4-yl)butyl]-3-(pyridin-3-yl)acrylamide;  
N-[4-(1-diphenylaminocarbonylpiperidin-4-yl)butyl]-5-(pyridin-3-yl)-2,4-pentadienic acid amide;  
N-{4-[1-(10,11-dihydrodibenzo[b,f]azepin-5-yl-carbonyl)piperidin-4-yl]-butyl}-3-(pyridin-3-yl)-acrylamide;  
N-[4-(1-diphenylphosphinoylpiperidin-4-yl)butyl]-3-(pyridin-3-yl)acrylamide;  
N-[4-(1-acetylpiperidin-4-yl)butyl]-3-(pyridin-3-yl)acrylamide;  
N-[4-(1-diphenylacetylpiperidin-4-yl)-butyl]-3-(pyridin-3-yl)acrylamide;  
N-{4-[1-(3,3-diphenylpropionyl)piperidin-4-yl]-butyl}-3-(pyridin-3-yl)acrylamide;  
N-[4-(1-benzoylpiperidin-4-yl)butyl]-3-(pyridin-3-yl)acrylamide;  
N-[4-(1-benzoylpiperidin-4-yl)butyl]-5-(pyridin-3-yl)-2,4-pentadienic acid amide;  
N-{4-[1-(9-oxo-9H-fluoren-4-ylcarbonyl)piperidin-4-yl]butyl}-3-(pyridin-3-yl)acrylamide;  
N-{4-[1-(phenylpyridin-3-ylmethyl)piperidin-4-yl]-butyl}-3-(pyridin-3-yl)acrylamide;  
N-{4-[1-(phenylpyridin-4-ylmethyl)piperidin-4-yl]-butyl}-3-(pyridin-3-yl)acrylamide;  
N-{4-[1-(6,11-dihydrodibenzo[b,e]oxepin-11-yl)piperidin-4-yl]butyl}-3-(pyridin-3-yl)acrylamide;  
N-{4-[1-(6,11-dihydrodibenzo[b,e]thiepin-11-yl)piperidin-4-yl]-butyl}-3-(pyridin-3-yl)acrylamide;  
N-[7-(1-diphenylmethylpiperidin-4-yl)heptyl]-3-(pyridin-3-yl)acrylamide;  
N-[8-(1-diphenylmethylpiperidin-4-yl)octyl]-3-(pyridin-3-yl)acrylamide;  
N-[3-(1-diphenylmethylpiperidin-4-yloxy)propyl]-3-(pyridin-3-yl)acrylamide;  
N-[3-(1-benzylpiperidin-4-yloxy)propyl]-3-(pyridin-3-yl)acrylamide;  
N-[2-(1-diphenylmethylpiperidin-4-yl)ethyl]-5-(pyridin-3-yl)-2,4-pentadienic acid amide;  
N-[4-(1-diphenylmethylpiperidin-4-yl)butyl]-5-(pyridin-3-yl)-2,4-pentadienic acid amide;  
N-[5-(1-diphenylmethylpiperidin-4-yl)pentyl]-5-(pyridin-3-yl)-2,4-pentadienic acid amide;  
N-[6-(1-diphenylmethylpiperidin-4-yl)hexyl]-5-(pyridin-3-yl)-2,4-pentadienic acid amide;  
N-[4-(4-diphenylmethylpiperazin-1-yl)-3-hydroxybutyl]-3-(pyridin-3-yl)acrylamide;  
N-[3-(4-diphenylmethylpiperazin-1-yl)propoxy]-3-(pyridin-3-yl)acrylamide;  
N-[4-(4-diphenylmethylpiperazin-1-yl)-4-oxobutyl]-3-(pyridin-3-yl)acrylamide;  
N-[3-(4-diphenylmethylpiperazin-1-sulfonyl)propyl]-3-(pyridin-3-yl)acrylamide;  
N-{2-[2-(4-diphenylmethylpiperazin-1-yl)ethoxy]ethyl}-3-(pyridin-3-yl)acrylamide;

Application No. 09/693,558

Page 22

N-(4-{4-[bis(4-fluorophenyl)methyl]piperazin-1-yl}but-2-enyl)-3-(pyridin-3-yl)acrylamide;  
N-(4-{4-[(4-carboxyphenyl)phenylmethyl]piperazin-1-yl}butyl)-3-(pyridin-3-yl)acrylamide;  
N-(4-{4-[(4-aminophenyl)phenylmethyl]piperazin-1-yl}butyl)-3-(pyridin-3-yl)acrylamide;  
N-{4-[4-(9H-fluoren-9-yl)piperazin-1-yl]butyl}-2-(pyridin-3-yloxy)acetamide;  
N-{5-[4-(9H-fluoren-9-yl)piperazin-1-yl]pentyl}-3-(pyridin-3-yl)acrylamide;  
N-{6-[4-(9H-fluoren-9-yl)piperazin-1-yl]hexyl}-3-(pyridin-3-yl)acrylamide;  
3-(pyridin-3-yl)-N-{4-[4-(1,2,3,4-tetrahydronaphthalen-1-yl)piperazin-1-yl]butyl}acrylamide;  
3-(pyridin-3-yl)-N-{4-[4-(5,6,7,8-tetrahydronaphthalen-1-yl)piperazin-1-yl]butyl}acrylamide;  
N-{4-[4-(naphthalen-1-yl)piperazin-1-yl]butyl}-3-(pyridin-3-yl)acrylamide;  
N-[4-(4-biphenyl-2-yl)piperazin-1-yl]butyl}-3-(pyridin-3-yl)propionamide;  
N-[5-(4-biphenyl-2-yl)piperazin-1-yl]pentyl}-3-(pyridin-3-yl)acrylamide;  
N-[6-(4-biphenyl-2-yl)piperazin-1-yl]hexyl}-3-(pyridin-3-yl)acrylamide;  
N-[4-(4-biphenyl-2-yl)piperazin-1-yl]butyl}-2-(pyridin-3-yloxy)acetamide;  
N-[4-(4-biphenyl-2-yl)piperazin-1-yl]butyl}-5-(pyridin-3-yl)-2,4-pentadienic acid amide;  
N-{4-[4-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)piperazin-1-yl]butyl}-3-(pyridin-3-yl)-propionamide;  
N-{5-[4-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)piperazin-1-yl]pentyl}-3-(pyridin-3-yl)-acrylamide;  
N-{6-[4-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)piperazin-1-yl]hexyl}-3-(pyridin-3-yl)-acrylamide;  
N-{4-[4-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)piperazin-1-yl]butyl}-5-(pyridin-3-yl)-2,4-pentadienic amide;  
N-{4-[4-(6,11-dihydrodibenzo[b,e]oxepin-11-yl)piperazin-1-yl]butyl}-3-(pyridin-3-yl)propionamide;  
N-{2-[4-(6,11-dihydrodibenzo[b,e]thiepin-11-yl)piperazin-1-yl]ethyl}-3-(pyridin-3-yl)acrylamide;  
N-[4-(4-diphenylacetyl)piperazin-1-yl]butyl}-3-(pyridin-3-yl)acrylamide;  
N-[4-(4-benzoylpiperazin-1-yl)butyl]-3-(pyridin-3-yl)acrylamide;  
N-{4-[4-(2-aminobenzoyl)piperazin-1-yl]butyl}-3-(pyridin-3-yl)acrylamide;  
N-{4-[4-(4-carboxybenzoyl)piperazin-1-yl]butyl}-3-(pyridin-3-yl)acrylamide;  
N-{4-[4-(biphenyl-2-carbonyl)piperazin-1-yl]butyl}-3-(pyridin-3-yl)acrylamide;  
N-{4-[4-(9-oxo-9H-fluoren-4-carbonyl)piperazin-1-yl]butyl}-3-(pyridin-3-yl)acrylamide;  
N-{4-[4-(furan-2-carbonyl)piperazin-1-yl]butyl}-3-(pyridin-3-yl)acrylamide;  
N-{4-[4-(naphthalen-1-ylaminocarbonyl)piperazin-1-yl]butyl}-3-(pyridin-3-yl)propionamide;

Application No. 09/693,558

Page 23

N-{4-[4-(diphenylaminocarbonyl)piperazin-1-yl]butyl}-3-(pyridin-3-yl)acrylamide;  
N-{4-[4-(naphthalen-2-sulfonyl)piperazin-1-yl]butyl}-3-(pyridin-3-yl)acrylamide;  
N-[4-(4-diphenylphosphinonylpiperazin-1-yl)butyl]-3-(pyridin-3-yl)acrylamide;  
N-[4-(4-biphenyl-2-ylpiperazin-1-yl)butyl]-3-(pyridin-3-yl)acrylamide;  
N-{4-[4-(9H-fluoren-9-yl)piperazin-1-yl]butyl}-3-(pyridin-3-yl)acrylamide;  
N-{4-[4-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)piperazin-1-yl]butyl}-3-(pyridin-3-yl)-  
acrylamide;  
N-[4-(4-phenylpiperidin-1-yl)-butyl]-3-(pyridin-3-yl)acrylamide;  
N-{4-[4-(1H-indol-3-yl)piperidin-1-yl]butyl}-3-(pyridin-3-yl)acrylamide;  
N-{4-[4-(2-oxo-2,3-dihydrobenzimidazol-1-yl)piperidin-1-yl]butyl}-3-(pyridin-3-yl)acrylamide;  
N-[4-(4-benzotriazol-1-ylpiperidin-1-yl)butyl]-3-(pyridin-3-yl)acrylamide;  
N-{4-[4-(hydroxydiphenylmethyl)piperidin-1-yl]butyl}-2-(pyridin-3-yloxy)acetamide;  
N-[4-(4,4-diphenylpiperidin-1-yl)butyl]-3-(pyridin-3-yl)acrylamide;  
N-{4-[4-(6,11-dihydrodibenzo[b,e]thiepin-11-yliden)piperidin-1-yl]butyl}-3-(pyridin-3-yl)propionamide  
dihydrochloride semi-isopropanol;  
N-{4-[4-(6,11-dihydrodibenzo[b,e]thiepin-11-yliden)piperidin-1-yl]butyl}-5-(pyridin-3-yl)pentanamide;  
N-{4-[4-(4,9-dihydrothieno[2,3-b]benzo[e]thiepin-4-yliden)piperidin-1-yl]butyl}-3-(pyridin-3-yl)-  
propionamide;  
N-{4-[4-(4,9-dihydrothieno[2,3-b]benzo[e]thiepin-4-yliden)piperidin-1-yl]butyl}-3-(pyridin-3-yl)-  
acrylamide;  
N-[4-(4-diphenylphosphinoyloxypiperidin-1-yl)butyl]-3-(pyridin-3-yl)acrylamide;  
N-[4-(1,4-dioxo-8-azaspiro[4.5]dec-8-yl)butyl]-3-(pyridin-3-yl)acrylamide;  
N-[4-(2,5-dioxo-3,4-diphenyl-2,5-dihydropyrrol-1-yl)butyl]-3-(pyridin-3-yl)acrylamide;  
N-[4-(2,6-dioxo-4-phenylpiperidin-1-yl)butyl]-3-(pyridin-3-yl)acrylamide;  
N-[4-(1,3-dioxo-4,5,6,7-tetraphenyl-1,3-dihydroisoindol-2-yl)butyl]-3-(pyridin-3-yl)acrylamide;  
N-[4-(3-benzyl-2,4,5-trioxoimidazolidin-1-yl)butyl]-3-(pyridin-3-yl)acrylamide;  
N-[4-(1,3,10-trioxo-1,4,5,6,10,10a-hexahydroacenaphtho[1,8a-c]pyrrol-2-yl)butyl]-3-(pyridin-3-yl)-  
acrylamide;  
N-[4-(2,5-dioxo-4,4-diphenylimidazolidin-1-yl)butyl]-3-(pyridin-3-yl)acrylamide;  
N-[4-(2,5-dioxo-3-phenyl-2,5-dihydropyrrol-1-yl)butyl]-3-(pyridin-3-yl)acrylamide;  
N-[3-(2,5-dioxo-3,4-diphenyl-2,5-dihydropyrrol-1-yl)propyl]-3-(pyridin-3-yl)acrylamide;  
N-[4-(3-pyridin-3-ylacryloylamino)butyl]-2,3,5,6-dibenzobicyclo[2.2.2]octan-7,8-dicarboximide;

Application No. 09/693,558

Page 24

N-[4-(5-benzyliden-2,4-dioxothiazolidin-3-yl)butyl]-3-(pyridin-3-yl)acrylamide;  
N-[4-(4-benzyl-2,6-dioxopiperazin-1-yl)butyl]-3-(pyridin-3-yl)acrylamide;  
N-[6-(2,5-dioxo-3,4-diphenyl-2,5-dihydropyrrol-1-yl)hexyl]-3-(pyridin-3-yl)acrylamide;  
N-[4-(2,5-dioxo-3,4-diphenyl-2,5-dihydropyrrol-1-yl)butyl]-3-(pyridin-3-yl)propionamide;  
N-[4-(1,3-dioxo-1,3-dihydroisoindol-2-yl)butyl]-3-(pyridin-3-yl)acrylamide;  
N-[4-(1,3-dioxo-1H,3H-benzo[de]isoquinolin-2-yl)butyl]-3-(1-oxopyridin-3-yl)acrylamide;  
N-[6-(1,3-dioxo-1H,3H-benzo[de]isoquinolin-2-yl)hexyl]-3-(pyridin-3-yl)acrylamide;  
N-[2-(1,3-dioxo-1H,3H-benzo[de]isoquinolin-2-yl)ethyl]-3-(pyridin-3-yl)acrylamide;  
N-[4-(1,3-dioxo-1H,3H-benzo[de]isoquinolin-2-yl)butyl]-3-(pyridin-3-yl)acrylamide;  
N-[8,8-bis(4-fluorophenyl)octyl]-3-(pyridin-3-yl)acrylamide hydrochloride;  
N-[6-(3,3-diphenylureido)hexyl]-3-(pyridin-3-yl)acrylamide;  
N-[4-(1-phenyl-1,2,4,5-tetrahydrobenzo[d]azepin-3-yl)butyl]-3-(pyridin-3-yl)acrylamide;  
N-(8,8-diphenyloctyl)-3-(pyridin-3-yl)acrylamide;  
N-(8-hydroxy-8,8-diphenyloctyl)-3-(pyridin-3-yl)acrylamide;  
N-[4-(3,3-diphenylureido)butyl]-3-(pyridin-3-yl)acrylamide;  
N-[4-(1H,3H-benzo[de]isoquinolin-2-yl)butyl]-3-(pyridin-3-yl)acrylamide;  
N-[6-(10,11-dihydrodibenzo[b,f]azepin-5-ylcarbonylamino)hexyl]-3-(pyridin-3-yl)acrylamide;  
3-(pyridin-3-yl)-N-[6-tosylaminoethyl]acrylamide;  
N-[4-(1,1-dioxo-1-thia-2-azaacenaphthylen-2-yl)butyl]-3-(pyridin-3-yl)acrylamide;  
N-(6-hydroxy-6,6-diphenylhexyl)-3-(pyridin-3-yl)acrylamide;  
N-(6,6-diphenylhex-5-enyl)-3-(pyridin-3-yl)acrylamide;  
N-[4-(4,5-diphenylimidazol-1-yl)butyl]-3-(pyridin-3-yl)acrylamide;  
N-[4-(trans-2-phenylcyclopropylcarbonylamino)butyl]-3-(pyridin-3-yl)acrylamide;  
N-(5-hydroxy-5,5-diphenylpentyl)-3-(pyridin-3-yl)acrylamide;  
N-(7-phenylheptyl)-3-(pyridin-3-yl)acrylamide;  
N-(4-diphenylacetylaminobutyl)-3-(pyridin-3-yl)acrylamide;  
N-[4-(benzhydrylamino)butyl]-3-(pyridin-3-yl)acrylamide; and  
N-(4-{[2-(benzhydrylmethylamino)ethyl]methylamino}butyl)-3-(pyridin-3-yl)acrylamide.

40.(Amended) The method of claim 50 38 comprising the additional administration of a further cancerostatic or immunosuppressive agent that is not a compound of formula Ia I.



42.(Amended) The composition of claim 52 4+ comprising a further cancerostatic or immunosuppressive agent that is not a compound of formula Ia I.

43. The composition of claim 52 4+ where the compound(s) of formula Ia I and the compound(s) of formula II - Vb are contained separately within the composition.

44. The composition of claim 52 4+ where the compound(s) of formula Ia I and the compound(s) of formula II - Vb are present in separate dosage forms, and the dosage forms are packaged together for co-administration.

45. The composition of claim 52 4+ where:

R<sup>21</sup> is selected from the group consisting of hydrogen, halogen, cyano, C<sub>1-6</sub> alkyl, trifluoromethyl, C<sub>1-6</sub> hydroxyalkyl, hydroxy, C<sub>1-6</sub> alkoxy, C<sub>2-7</sub> alkanoyloxy, C<sub>1-6</sub> alkylthio, C<sub>1-6</sub> aminoalkyl, amino, C<sub>1-6</sub> alkylamino, di(C<sub>1-6</sub> alkyl)amino, formyl, alkoxycarbonyl, aminocarbonyl, (C<sub>1-6</sub> alkyl)aminocarbonyl, di(C<sub>1-6</sub> alkyl)aminocarbonyl, and carboxy;

R<sup>22</sup> is selected from the group consisting of hydrogen, halogen, C<sub>1-6</sub> alkyl, trifluoromethyl, C<sub>1-6</sub> hydroxyalkyl, hydroxy, alkoxy, C<sub>2-7</sub> alkanoyloxy, C<sub>1-6</sub> aminoalkyl, amino, (C<sub>1-6</sub> alkoxy)carbonyl, aminocarbonyl, and carboxy;

R<sup>23</sup> is selected from the group consisting of hydrogen, C<sub>1-6</sub> alkyl, and C<sub>1-6</sub> hydroxyalkyl;

R<sup>24</sup> is selected from the group consisting of C<sub>1-6</sub> alkyl, C<sub>3-6</sub> alkenyl, C<sub>2-6</sub> hydroxyalkyl, C<sub>2-6</sub> alkoxyalkyl, and benzyl;

R<sup>26</sup> is selected from the group consisting of hydrogen, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> hydroxyalkyl, C<sub>3-6</sub> alkoxyalkyl, C<sub>1-6</sub> aminoalkyl, C<sub>4-12</sub> dialkylaminoalkyl, and carboxymethyl;

when b is 1, R<sup>27</sup> is selected from the group consisting of hydrogen, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> hydroxyalkyl, C<sub>3-6</sub> alkoxyalkyl, C<sub>1-6</sub> aminoalkyl, C<sub>4-12</sub> dialkylaminoalkyl, and carboxymethyl;

when b is 2, R<sup>27</sup> is C<sub>2-10</sub> alkylene in which a methylene group is optionally replaced by O, NH, or N-alkyl.

46. The composition of claim 52 4+ where the compound having vitamin PP activity or a prodrug thereof is selected from the group consisting of nicotinic acid, nicotinamide, and their pharmaceutically acceptable ester and amide derivatives, anionic, quaternary, and addition salts, N-oxides, and analogous thioxo derivatives, their isomers, and prodrugs thereof.

Application No. 09/693,558

Page 26

48. (Amended) The composition of claim 51 46 where the compound having vitamin PP activity or a prodrug thereof is tryptophan.

49. The composition of claim 52 44 where ~~the compound(s) of formula Ia are cancerostatic or immunosuppressive agent~~ is selected from the group consisting of

N-[2-(1-benzylpiperidin-4-yl)ethyl]-3-(pyridin-3-yl)propionamide;  
N-{2-[1-(2-phenylethyl)piperidin-4-yl]ethyl}-3-(pyridin-3-yl)propionamide;  
N-{2-[1-(4-phenylbutyl)piperidin-4-yl]ethyl}-3-(pyridin-3-yl)propionamide;  
N-{2-[1-(4-hydroxy-4-phenylbutyl)piperidin-4-yl]ethyl}-3-(pyridin-3-yl)propionamide;  
N-[2-(1-diphenylmethylpiperidin-4-yl)ethyl]-3-(pyridin-3-yl)propionamide;  
N-[3-(1-diphenylmethylpiperidin-4-yl)propyl]-3-(pyridin-3-yl)propionamide;  
N-[4-(1-diphenylmethylpiperidin-4-yl)butyl]-3-(pyridin-3-yl)propionamide;  
N-[4-(1-benzylpiperidin-4-yl)butyl]-3-(pyridin-3-yl)acrylamide;  
N-{4-[1-(2-phenylethyl)piperidin-4-yl]butyl}-3-(pyridin-3-yl)acrylamide;  
N-{4-[1-(4-biphenylmethyl)piperidin-4-yl]butyl}-3-(pyridin-3-yl)acrylamide;  
N-{4-[1-(1-naphthylmethyl)piperidin-4-yl]butyl}-3-(pyridin-3-yl)acrylamide;  
N-{4-[1-(9-anthrylmethyl)piperidin-4-yl]butyl}-3-(pyridin-3-yl)acrylamide;  
N-{4-[1-(cyclohexylphenylmethyl)piperidin-4-yl]butyl}-3-(pyridin-3-yl)acrylamide;  
N-{4-[1-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)piperidin-4-yl]butyl}-3-(pyridin-3-yl)-acrylamide;  
N-[2-(1-diphenylmethylpiperidin-4-yl)ethyl]-3-(pyridin-3-yl)acrylamide;  
N-[3-(1-diphenylmethylpiperidin-4-yl)propyl]-3-(pyridin-3-yl)acrylamide;  
N-[5-(1-diphenylmethylpiperidin-4-yl)pentyl]-3-(pyridin-3-yl)acrylamide;  
N-[6-(1-diphenylmethylpiperidin-4-yl)hexyl]-3-(pyridin-3-yl)acrylamide;  
N-[4-(1-diphenylmethylpiperidin-4-yl)butyl]-5-(pyridin-3-yl)-2,4-pentadienic acid amide;  
N-(4-{1-[bis(4-fluorophenyl)methyl]piperidin-4-yl}butyl)-3-(pyridin-3-yl)acrylamide;  
N-(4-{1-[bis(2-chlorophenyl)methyl]piperidin-4-yl}butyl)-3-(pyridin-3-yl)acrylamide;  
N-[4-(1-diphenylmethylpiperidin-4-yl)butyl]-3-(2-fluoro-pyridin-3-yl)acrylamide;  
N-[4-(1-diphenylmethylpiperidin-4-yl)butyl]-3-(6-fluoro-pyridin-3-yl)acrylamide;  
N-[4-(1-diphenylmethylpiperidin-4-yl)butyl]-3-(pyridin-3-yl)acrylamide;  
N-[4-(1-diphenylmethylpiperidin-4-yl)butyl]-3-(pyridin-3-yl)acrylamide dihydrochloride;  
N-[4-(1-diphenylmethylpiperidin-4-yl)butyl]-3-(pyridin-3-yl)acrylamide methanesulfonate;

Application No. 09/693,558

Page 27

N-[4-(1-acetylpiiperidin-4-yl)butyl]-3-(pyridin-3-yl)propionamide;  
N-[4-(1-benzoylpiiperidin-4-yl)butyl]-3-(pyridin-3-yl)propionamide;  
N-[4-(1-diphenylacetylpiiperidin-4-yl)butyl]-3-(pyridin-3-yl)propionamide;  
N-{4-[1-(9-oxo-9H-fluoren-4-carbonyl)piiperidin-4-yl]butyl}-3-(pyridin-3-yl)propionamide;  
N-[4-(1-methylsulfonylpiiperidin-4-yl)butyl]-3-(pyridin-3-yl)propionamide;  
N-{4-[1-(2-naphthylsulfonyl)piiperidin-4-yl]butyl}-3-(pyridin-3-yl)propionamide;  
N-[4-(1-benzylpiiperidin-4-yl)butyl]-3-(pyridin-3-yl)propionamide;  
N-(4-{1-[bis(2-chlorophenyl)methyl]piiperidin-4-yl}butyl)-3-(pyridin-3-yl)propionamide;  
N-{4-[1-(phenylpyridin-3-ylmethyl)piiperidin-4-yl]butyl}-3-(pyridin-3-yl)propionamide;  
N-{4-[1-(9H-fluoren-9-yl)piiperidin-4-yl]butyl}-3-(pyridin-3-yl)propionamide;  
N-{4-[1-(6,11-dihydrodibenzo[b,e]oxepin-11-yl)piiperidin-4-yl]butyl}-3-(pyridin-3-yl)propionamide;  
N-{4-[1-(1-naphthylaminocarbonyl)piiperidin-4-yl]butyl}-3-(pyridin-3-yl)propionamide;  
N-[4-(1-diphenylaminocarbonylpiiperidin-4-yl)butyl]-3-(pyridin-3-yl)propionamide;  
N-{4-[1-(10,11-dihydrodibenzo[b,f]azepin-5-yl-carbonyl)piiperidin-4-yl]butyl}-3-(pyridin-3-yl)-  
propionamide;  
N-[4-(1-diphenylphosphinoylpiiperidin-4-yl)butyl]-3-(pyridin-3-yl)propionamide;  
N-[4-(1-diphenylmethylpiiperidin-4-yl)butyl]-3-(2-fluoropyridin-3-yl)propionamide;  
N-[4-(1-diphenylmethylpiiperidin-4-yl)butyl]-3-(5-fluoropyridin-3-yl)propionamide;  
N-[4-(1-diphenylmethylpiiperidin-4-yl)butyl]-2-fluoro-3-(pyridin-3-yl)propionamide;  
N-[4-(1-diphenylmethylpiiperidin-4-yl)butyl]-2,2-difluoro-3-(pyridin-3-yl)propionamide;  
N-[5-(1-diphenylmethylpiiperidin-4-yl)pentyl]-3-(pyridin-3-yl)propionamide;  
N-[6-(1-diphenylmethylpiiperidin-4-yl)hexyl]-3-(pyridin-3-yl)propionamide;  
N-[2-(1-diphenylmethylpiiperidin-4-yl)ethyl]-5-(pyridin-3-yl)pentanoic acid amide;  
N-[4-(1-diphenylmethylpiiperidin-4-yl)butyl]-5-(pyridin-3-yl)pentanoic acid amide;  
N-[4-(1-diphenylmethylpiiperidin-4-yl)butyl]-N-hydroxy-3-(pyridin-3-yl)propionamide;  
N-[4-(1-diphenylmethylpiiperidin-4-yl)butyl]-2-hydroxy-3-(pyridin-3-yl)propionamide;  
N-{4-(1-diphenylmethylpiiperidin-4-yl)butyl}-3-hydroxy-3-(pyridin-3-yl)propionamide;  
N-[4-(1-diphenylmethylpiiperidin-4-yl)butyl]-3-(pyridin-3-yl)propionamide;  
N-[4-(1-methylsulfonylpiiperidin-4-yl)butyl]-3-(pyridin-3-yl)acrylamide;  
N-{4-[1-(2-naphthylsulfonyl)piiperidin-4-yl]butyl}-3-(pyridin-3-yl)acrylamide;  
N-{4-[1-(2-naphthylsulfonyl)piiperidin-4-yl]butyl}-5-(pyridin-3-yl)-2,4-pentadienic acid amide;  
N-{4-[1-(1-naphthylaminocarbonyl)piiperidin-4-yl]butyl}-3-(pyridin-3-yl)acrylamide;

Application No. 09/693,558

Page 28

N-[4-(1-diphenylaminocarbonylpiperidin-4-yl)butyl]-3-(pyridin-3-yl)acrylamide;  
N-[4-(1-diphenylaminocarbonylpiperidin-4-yl)butyl]-5-(pyridin-3-yl)-2,4-pentadienic acid amide;  
N-{4-[1-(10,11-dihydrodibenzo[b,f]azepin-5-yl-carbonyl)piperidin-4-yl]-butyl}-3-(pyridin-3-yl)-acrylamide;  
N-[4-(1-diphenylphosphinoylpiperidin-4-yl)butyl]-3-(pyridin-3-yl)acrylamide;  
N-[4-(1-acetylpiperidin-4-yl)butyl]-3-(pyridin-3-yl)acrylamide;  
N-[4-(1-diphenylacetylpiperidin-4-yl)-butyl]-3-(pyridin-3-yl)acrylamide;  
N-{4-[1-(3,3-diphenylpropionyl)piperidin-4-yl]-butyl}-3-(pyridin-3-yl)acrylamide;  
N-[4-(1-benzoylpiperidin-4-yl)butyl]-3-(pyridin-3-yl)acrylamide;  
N-[4-(1-benzoylpiperidin-4-yl)butyl]-5-(pyridin-3-yl)-2,4-pentadienic acid amide;  
N-{4-[1-(9-oxo-9H-fluoren-4-ylcarbonyl)piperidin-4-yl]butyl}-3-(pyridin-3-yl)acrylamide;  
N-{4-[1-(phenylpyridin-3-ylmethyl)piperidin-4-yl]butyl}-3-(pyridin-3-yl)acrylamide;  
N-{4-[1-(phenylpyridin-4-ylmethyl)piperidin-4-yl]butyl}-3-(pyridin-3-yl)acrylamide;  
N-{4-[1-(6,11-dihydrodibenzo[b,e]oxepin-11-yl)piperidin-4-yl]butyl}-3-(pyridin-3-yl)acrylamide;  
N-{4-[1-(6,11-dihydrodibenzo[b,e]thiepin-11-yl)piperidin-4-yl]butyl}-3-(pyridin-3-yl)acrylamide;  
N-[7-(1-diphenylmethylpiperidin-4-yl)heptyl]-3-(pyridin-3-yl)acrylamide;  
N-[8-(1-diphenylmethylpiperidin-4-yl)octyl]-3-(pyridin-3-yl)acrylamide;  
N-[3-(1-diphenylmethylpiperidin-4-yloxy)propyl]-3-(pyridin-3-yl)acrylamide;  
N-[3-(1-benzylpiperidin-4-yloxy)propyl]-3-(pyridin-3-yl)acrylamide;  
N-[2-(1-diphenylmethylpiperidin-4-yl)ethyl]-5-(pyridin-3-yl)-2,4-pentadienic acid amide;  
N-[4-(1-diphenylmethylpiperidin-4-yl)butyl]-5-(pyridin-3-yl)-2,4-pentadienic acid amide;  
N-[5-(1-diphenylmethylpiperidin-4-yl)pentyl]-5-(pyridin-3-yl)-2,4-pentadienic acid amide;  
N-[6-(1-diphenylmethylpiperidin-4-yl)hexyl]-5-(pyridin-3-yl)-2,4-pentadienic acid amide;  
N-[4-(4-diphenylmethylpiperazin-1-yl)-3-hydroxybutyl]-3-(pyridin-3-yl)acrylamide;  
N-[3-(4-diphenylmethylpiperazin-1-yl)propoxy]-3-(pyridin-3-yl)acrylamide;  
N-[4-(4-diphenylmethylpiperazin-1-yl)-4-oxobutyl]-3-(pyridin-3-yl)acrylamide;  
N-[3-(4-diphenylmethylpiperazin-1-sulfonyl)propyl]-3-(pyridin-3-yl)acrylamide;  
N-{2-[2-(4-diphenylmethylpiperazin-1-yl)ethoxy]ethyl}-3-(pyridin-3-yl)acrylamide;  
N-(4-{4-[bis(4-fluorophenyl)methyl]piperazin-1-yl}but-2-enyl)-3-(pyridin-3-yl)acrylamide;  
N-(4-{4-[(4-carboxyphenyl)phenylmethyl]piperazin-1-yl}butyl)-3-(pyridin-3-yl)acrylamide;  
N-(4-{4-[(4-aminophenyl)phenylmethyl]piperazin-1-yl}butyl)-3-(pyridin-3-yl)acrylamide;  
N-{4-[4-(9H-fluoren-9-yl)piperazin-1-yl]butyl}-2-(pyridin-3-yloxy)acetamide;

Application No. 09/693,558

Page 29

N-{5-[4-(9H-fluoren-9-yl)piperazin-1-yl]pentyl}-3-(pyridin-3-yl)acrylamide;  
N-{6-[4-(9H-fluoren-9-yl)piperazin-1-yl]hexyl}-3-(pyridin-3-yl)acrylamide;  
3-(pyridin-3-yl)-N-{4-[4-(1,2,3,4-tetrahydronaphthalen-1-yl)piperazin-1-yl]butyl}acrylamide;  
3-(pyridin-3-yl)-N-{4-[4-(5,6,7,8-tetrahydronaphthalen-1-yl)piperazin-1-yl]butyl}acrylamide;  
N-{4-[4-(naphthalen-1-yl)piperazin-1-yl]butyl}-3-(pyridin-3-yl)acrylamide;  
N-[4-(4-biphenyl-2-ylpiperazin-1-yl)butyl]-3-(pyridin-3-yl)propionamide;  
N-[5-(4-biphenyl-2-ylpiperazin-1-yl)pentyl]-3-(pyridin-3-yl)acrylamide;  
N-[6-(4-biphenyl-2-ylpiperazin-1-yl)hexyl]-3-(pyridin-3-yl)acrylamide;  
N-[4-(4-biphenyl-2-ylpiperazin-1-yl)butyl]-2-(pyridin-3-yloxy)acetamide;  
N-[4-(4-biphenyl-2-ylpiperazin-1-yl)butyl]-5-(pyridin-3-yl)-2,4-pentadienic acid amide;  
N-{4-[4-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)piperazin-1-yl]butyl}-3-(pyridin-3-yl)-propionamide;  
N-{5-[4-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)piperazin-1-yl]pentyl}-3-(pyridin-3-yl)-acrylamide;  
N-{6-[4-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)piperazin-1-yl]hexyl}-3-(pyridin-3-yl)-acrylamide;  
N-{4-[4-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)piperazin-1-yl]butyl}-5-(pyridin-3-yl)-2,4-pentadienic amide;  
N-{4-[4-(6,11-dihydrodibenzo[b,e]oxepin-11-yl)piperazin-1-yl]butyl}-3-(pyridin-3-yl)propionamide;  
N-{2-[4-(6,11-dihydrodibenzo[b,e]thiepin-11-yl)piperazin-1-yl]ethyl}-3-(pyridin-3-yl)acrylamide;  
N-[4-(4-diphenylacetyl)piperazin-1-yl]butyl]-3-(pyridin-3-yl)acrylamide;  
N-[4-(4-benzoyl)piperazin-1-yl]butyl]-3-(pyridin-3-yl)acrylamide;  
N-{4-[4-(2-aminobenzoyl)piperazin-1-yl]butyl}-3-(pyridin-3-yl)acrylamide;  
N-{4-[4-(4-carboxybenzoyl)piperazin-1-yl]butyl}-3-(pyridin-3-yl)acrylamide;  
N-{4-[4-(biphenyl-2-carbonyl)piperazin-1-yl]butyl}-3-(pyridin-3-yl)acrylamide;  
N-{4-[4-(9-oxo-9H-fluoren-4-carbonyl)piperazin-1-yl]butyl}-3-(pyridin-3-yl)acrylamide;  
N-{4-[4-(furan-2-carbonyl)piperazin-1-yl]butyl}-3-(pyridin-3-yl)acrylamide;  
N-{4-[4-(naphthalen-1-ylaminocarbonyl)piperazin-1-yl]butyl}-3-(pyridin-3-yl)propionamide;  
N-{4-[4-(diphenylaminocarbonyl)piperazin-1-yl]butyl}-3-(pyridin-3-yl)acrylamide;  
N-{4-[4-(naphthalen-2-sulfonyl)piperazin-1-yl]butyl}-3-(pyridin-3-yl)acrylamide;  
N-[4-(4-diphenylphosphinonyl)piperazin-1-yl]butyl]-3-(pyridin-3-yl)acrylamide;  
N-[4-(4-biphenyl-2-ylpiperazin-1-yl)butyl]-3-(pyridin-3-yl)acrylamide;

Application No. 09/693,558

Page 30

N-{4-[4-(9H-fluoren-9-yl)piperazin-1-yl]butyl}-3-(pyridin-3-yl)acrylamide;  
N-{4-[4-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)piperazin-1-yl]butyl}-3-(pyridin-3-yl)-acrylamide;  
N-[4-(4-phenylpiperidin-1-yl)-butyl]-3-(pyridin-3-yl)acrylamide;  
N-{4-[4-(1H-indol-3-yl)piperidin-1-yl]butyl}-3-(pyridin-3-yl)acrylamide;  
N-{4-[4-(2-oxo-2,3-dihydrobenzimidazol-1-yl)piperidin-1-yl]butyl}-3-(pyridin-3-yl)acrylamide;  
N-[4-(4-benzotriazol-1-yl)piperidin-1-yl]butyl]-3-(pyridin-3-yl)acrylamide;  
N-{4-[4-(hydroxydiphenylmethyl)piperidin-1-yl]butyl}-2-(pyridin-3-yloxy)acetamide;  
N-[4-(4,4-diphenylpiperidin-1-yl)butyl]-3-(pyridin-3-yl)acrylamide;  
N-{4-[4-(6,11-dihydrodibenzo[b,c]thiepin-11-yliden)piperidin-1-yl]butyl}-3-(pyridin-3-yl)propionamide dihydrochloride semi-isopropanol;  
N-{4-[4-(6,11-dihydrodibenzo[b,e]thiepin-11-yliden)piperidin-1-yl]butyl}-5-(pyridin-3-yl)pentanamide;  
N-{4-[4-(4,9-dihydrothieno[2,3-b]benzo[e]thiepin-4-yliden)piperidin-1-yl]butyl}-3-(pyridin-3-yl)-propionamide;  
N-{4-[4-(4,9-dihydrothieno[2,3-b]benzo[e]thiepin-4-yliden)piperidin-1-yl]butyl}-3-(pyridin-3-yl)-acrylamide;  
N-[4-(4-diphenylphosphinoyloxypiperidin-1-yl)butyl]-3-(pyridin-3-yl)acrylamide;  
N-[4-(1,4-dioxo-8-azaspiro[4.5]dec-8-yl)butyl]-3-(pyridin-3-yl)acrylamide;  
N-[4-(2,5-dioxo-3,4-diphenyl-2,5-dihydropyrrol-1-yl)butyl]-3-(pyridin-3-yl)acrylamide;  
N-[4-(2,6-dioxo-4-phenylpiperidin-1-yl)butyl]-3-(pyridin-3-yl)acrylamide;  
N-[4-(1,3-dioxo-4,5,6,7-tetraphenyl-1,3-dihydroisindol-2-yl)butyl]-3-(pyridin-3-yl)acrylamide;  
N-[4-(3-benzyl-2,4,5-trioxoimidazolidin-1-yl)butyl]-3-(pyridin-3-yl)acrylamide;  
N-[4-(1,3,10-trioxo-1,4,5,6,10,10a-hexahydroacenaphtho[1,8a-c]pyrrol-2-yl)butyl]-3-(pyridin-3-yl)-acrylamide;  
N-[4-(2,5-dioxo-4,4-diphenylimidazolidin-1-yl)butyl]-3-(pyridin-3-yl)acrylamide;  
N-[4-(2,5-dioxo-3-phenyl-2,5-dihydropyrrol-1-yl)butyl]-3-(pyridin-3-yl)acrylamide;  
N-[3-(2,5-dioxo-3,4-diphenyl-2,5-dihydropyrrol-1-yl)propyl]-3-(pyridin-3-yl)acrylamide;  
N-[4-(3-pyridin-3-ylacryloylamino)butyl]-2,3:5,6-dibenzobicyclo[2.2.2]octan-7,8-dicarboximide;  
N-[4-(5-benzyliden-2,4-dioxothiazolidin-3-yl)butyl]-3-(pyridin-3-yl)acrylamide;  
N-[4-(4-benzyl-2,6-dioxopiperazin-1-yl)butyl]-3-(pyridin-3-yl)acrylamide;  
N-[6-(2,5-dioxo-3,4-diphenyl-2,5-dihydropyrrol-1-yl)hexyl]-3-(pyridin-3-yl)acrylamide;  
N-[4-(2,5-dioxo-3,4-diphenyl-2,5-dihydropyrrol-1-yl)butyl]-3-(pyridin-3-yl)propionamide;

Application No. 09/693,558


Page 31

N-[4-(1,3-dioxo-1,3-dihydroisoindol-2-yl)butyl]-3-(pyridin-3-yl)acrylamide;  
N-[4-(1,3-dioxo-1H,3H-benzo[de]isoquinolin-2-yl)butyl]-3-(1-oxopyridin-3-yl)acrylamide;  
N-[6-(1,3-dioxo-1H,3H-benzo[de]isoquinolin-2-yl)hexyl]-3-(pyridin-3-yl)acrylamide;  
N-[2-(1,3-dioxo-1H,3H-benzo[de]isoquinolin-2-yl)ethyl]-3-(pyridin-3-yl)acrylamide;  
N-[4-(1,3-dioxo-1H,3H-benzo[de]isoquinolin-2-yl)butyl]-3-(pyridin-3-yl)acrylamide;  
N-[8,8-bis(4-fluorophenyl)octyl]-3-(pyridin-3-yl)acrylamide hydrochloride;  
N-[6-(3,3-diphenylureido)hexyl]-3-(pyridin-3-yl)acrylamide;  
N-[4-(1-phenyl-1,2,4,5-tetrahydrobenzo[d]azepin-3-yl)butyl]-3-(pyridin-3-yl)acrylamide;  
N-(8,8-diphenyloctyl)-3-(pyridin-3-yl)acrylamide;  
N-(8-hydroxy-8,8-diphenyloctyl)-3-(pyridin-3-yl)acrylamide;  
N-[4-(3,3-diphenylurcido)butyl]-3-(pyridin-3-yl)acrylamide;  
N-[4-(1H,3H-benzo[de]isoquinolin-2-yl)butyl]-3-(pyridin-3-yl)acrylamide;  
N-[6-(10,11-dihydrodibenzo[b,f]azepin-5-ylcarbonylamino)hexyl]-3-(pyridin-3-yl)acrylamide;  
3-(pyridin-3-yl)-N-[6-tosylaminoethyl]acrylamide;  
N-[4-(1,1-dioxo-1-thia-2-azaacenaphthylen-2-yl)butyl]-3-(pyridin-3-yl)acrylamide;  
N-(6-hydroxy-6,6-diphenylhexyl)-3-(pyridin-3-yl)acrylamide;  
N-(6,6-diphenylhex-5-enyl)-3-(pyridin-3-yl)acrylamide;  
N-[4-(4,5-diphenylimidazol-1-yl)butyl]-3-(pyridin-3-yl)acrylamide;  
N-[4-(trans-2-phenylcyclopropylcarbonylamino)butyl]-3-(pyridin-3-yl)acrylamide;  
N-(5-hydroxy-5,5-diphenylpentyl)-3-(pyridin-3-yl)acrylamide;  
N-(7-phenylheptyl)-3-(pyridin-3-yl)acrylamide;  
N-(4-diphenylacetylaminobutyl)-3-(pyridin-3-yl)acrylamide;  
N-[4-(benzhydrylamino)butyl]-3-(pyridin-3-yl)acrylamide; and  
N-(4-{[2-(benzhydrylmethylamino)ethyl]methylamino}butyl)-3-(pyridin-3-yl)acrylamide.

PATENTS  
Attorney Docket No. 25846-0003  
FORMAL COMMUNICATION

## CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this paper is being transmitted by facsimile to the US PTO at fax number 703-872-9306 on October 10, 2002.

  
Derek P. Freyberg, Reg. No. 29,250

10/10/02  
Date

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Elfi Beidermann et al. : Confirmation No.: 7777  
App. No.: 09/693,558 : Art Unit: 1614  
Filed: October 20, 2000 : Examiner: Phyllis G. Spivack  
For: Use of vitamin PP compounds

Commissioner for Patents  
Washington, DC 20231

Sir:

## INFORMATION DISCLOSURE STATEMENT

Applicant directs the attention of the Office to the document listed on the attached Form PTO-1449 substitute, that may be relevant to the examination of this application.

The document is the complete article by Pozzilli et al. (document A6 of the IDS filed June 21, 2001) of which only an Erratum was previously supplied.

The Examiner is requested to initial and return a copy of the form with the next communication relating to this application.



App. No. 09/693,558

Page 2

No representation is made by this Information Disclosure Statement that a search has been made; or that the information disclosed is, or is considered to be, material to patentability under 37 CFR 1.56(b).

Respectfully submitted,



Derek P. Freyberg  
Attorney for Applicant  
Reg. No. 29,250

Heller Ehrman White & McAuliffe LLP  
275 Middlefield Road  
Menlo Park CA 94025-3506  
(650) 324-7014  
October 10, 2002

382628 v01.SV (878K011.DOC)  
10/10/02 4:05 PM0

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**